Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 18/20 | 0.36 |
| ▸ | TDO2 | P48775 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1106695 | 0.83 | CYP11B2 (0.43) | CYP11B2IDO1TDO2CYP3A4CYP2D6 | |
| SCHEMBL1097865 | 0.83 | CYP11B2 (0.58) | CYP11B2IDO1TDO2CYP3A4CYP2D6 | |
| SCHEMBL1098362 | 0.83 | CYP11B2 (0.58) | CYP11B2IDO1TDO2CYP3A4CYP2D6 | |
| SCHEMBL1106700 | 0.80 | CYP11B2 (0.45) | CYP11B2IDO1TDO2CYP3A4CYP2D6 | |
| SCHEMBL1106696 | 0.80 | CYP11B2 (0.48) | CYP11B2IDO1TDO2CYP3A4CYP2D6 | |
| SCHEMBL1106703 | 0.78 | CYP11B2 (0.46) | CYP11B2IDO1TDO2CYP3A4CYP2D6 | |
| SCHEMBL1106691 | 0.78 | CYP11B2 (0.48) | CYP11B2IDO1TDO2CYP3A4CYP2D6 | |
| SCHEMBL1097375 | 0.72 | CYP11B2 (0.59) | CYP11B2IDO1TDO2 | |
| SCHEMBL1106698 | 0.72 | CYP11B2 (0.46) | CYP11B2IDO1TDO2CYP3A4CYP2D6 | |
| SCHEMBL1106694 | 0.69 | CYP11B2 (0.58) | CYP11B2IDO1TDO2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153674-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-8153674-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-20090182007-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| US-20090182007-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| WO-2007117982-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182007-A1 | ORGANIC COMPOUNDS | REN, CYP17A1, HSD17B1 | CYP11B2 28/4885IDO1 2430/4885TDO2 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.